4Theocharis AD, Theocharis DA, De Luca G, et al.Compositional and structural alterations of chondroitin and dermatan sulfates during the progression of atherosclerosis and aneurysmal dilatation of the human abdominal aorta[J]. Biochimie, 2002,84(7):667.
5Kaplan M, Aviram M. Macrophage plasma membrane chondroitin sulfate proteoglycan binds oxidized low-density lipoprotein[J]. Atherosclerosis, 2000,149 (1): 5.
6Sartipy P, Bondiers G, Hurt-Camejo E. Phospholipase A2 type Ⅱ binds to extracellular matrix biglycan:modulation of its activity on LDL by colocalization in glycosaminoglycan matrixes[J]. Arterioscler Thromb Vasc Biol, 1998,18(12):1934.
7Anber V, Millar JS, McConnell M, et al. Interaction of very-low-density, intermediate-density, and lowdensity lipoproteins with human arterial wall proteoglycans[J]. Arterioscler Thromb Vasc Biol, 1997,17(11):2507.
8Olsson U, Ostergren-Lunden G, Moses J. Glycosaminoglycan lipoprotein interaction [J]. Glycoconj J,2001,18(10) : 789.
9Tirziu D, Jinga VV, Serban G, et al. The effects of low density lipoproteins modified by incubation with chondroitin 6-sulfate on human aortic smooth muscle cells[J].Atherosclerosis, 1999,147(1):155.
10Verbruggen G, Goemaere S, Veys E, et al. Chondroitin sulfate:S/DMOAD (structure/disease modifying anti-osteoarthritis drug)in the treatment of finger ioint OA[J]. Osteoarthritis Cartilage, 1998,6( Suppl A) :37.
